ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
Rhea-AI Summary
ANI Pharmaceuticals (NASDAQ: ANIP) has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's presentation is scheduled for Tuesday, May 20, 2025, at 1:30pm ET. CEO Nikhil Lalwani and CFO Stephen Carey will represent the company at the conference.
Investors can access the presentation through a live webcast on ANI's website under the Investors section. The webcast recording will remain available for 90 days after the event. One-on-one meetings with management can be arranged through meetings@hcwco.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANIP declined 0.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:
| Date: | Tuesday, May 20, 2025 |
| Time: | 1:30pm ET |
| Webcast: | Click Here |
To schedule a 1x1 meeting with management, please contact meetings@hcwco.com.
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: ANI Pharmaceuticals, Inc.
FAQ
When is ANI Pharmaceuticals (ANIP) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will be presenting for ANI Pharmaceuticals at the H.C. Wainwright Conference?
How can investors access ANI Pharmaceuticals' presentation at the BioConnect Conference?
How long will the replay of ANI Pharmaceuticals' BioConnect Conference presentation be available?
